Effects of brief acceptance and commitment therapy (ACT) on subjective cognitive impairment in breast cancer patients undergoing chemotherapy

2020 ◽  
pp. 1-30
Author(s):  
Nurul Izzah Shari ◽  
Nor Zuraida Zainal ◽  
Chong Guan Ng
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Acceptance And Commitment Therapy ◽  
Breast Cancer Patients ◽  
Subjective Cognitive Impairment ◽  
Commitment Therapy ◽  
Acceptance And Commitment

scholarly journals Membangun Body Image Melalui Acceptance and Commitment Therapy (ACT) pada Pasien Kanker Payudara

2020 ◽  
Vol 12 (1) ◽  
pp. 13-26
Author(s):  
Ria Rizki Utami ◽  
Iswinarti Iswinarti ◽  
Djudiah Djudiah
Keyword(s):  
Breast Cancer ◽  
Body Image ◽  
Cancer Patients ◽  
Acceptance And Commitment Therapy ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Control Group Design ◽  
Positive Body Image ◽  
Commitment Therapy ◽  
Acceptance And Commitment

Post-treatment for cancer patients have an impact on psychological discomfort, changes in lifestyle, fear and anxiety. One effect that often arises in breast cancer patients is a negative assessment of post-masectomy appearance such as breast removal. Development of body image problems related to low self acceptance in cancer patients. Interventions used to build a positive body image through acceptance and commitment therapy (ACT) in breast cancer patients. The design of study used a pretest-post-test control group design and the subjects involved in this study were breast cancer patients who were undergoing treatment at the age range of 30-50 years and had low score on body image scale. The data analysis method uses non-parametric analysis (Wilcoxon and Mann Whitney test) with SPSS. The results showed that ACT had an influence on body image in breast cancer patients. That is, ACT is able to build a positive body image in breast cancer patients

scholarly journals Chemotherapy-related subjective cognitive impairment in breast cancer patients in semi-rural South Africa

2021 ◽  
Vol 26 ◽  
Author(s):  
Nicholas M. Keetile ◽  
Elzbieta Osuch ◽  
Antonio G. Lentoor
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Current Evidence ◽  
Breast Cancer Patients ◽  
Rural South ◽  
Subjective Cognitive Impairment ◽  
Treatment Groups ◽  
Therapeutic Benefits ◽  
African Patients

Background: Breast cancer is the most commonly diagnosed cancer amongst women worldwide. Whilst current evidence indicates the therapeutic benefits from the use of chemotherapy, self-perceived cognitive difficulties emerged as a frequent occurrence during and after chemotherapy treatment in breast cancer patients.Aim: The current study sought to investigate self-perceived cognitive impairment in a group of breast cancer patients in semi-rural South Africa.Setting: The patients were recruited from an outpatient oncology clinic at a semi-rural, tertiary academic hospital in Gauteng, South Africa.Methods: In a randomised, quantitative, time-based series study, 30 female patients aged 21–60 years (mean age = 50 years) diagnosed with stages II and III breast cancer on CMF (cyclophosphamide, methotrexate, fluorouracil) (n = 10) and FAC (fluorouracil, adriamycin, cyclophosphamide) (n = 20) chemotherapy regimens, completed the self-reported Functional Assessment of Cancer Therapy-Cognition (Fact-Cog) test as a measure of subjective cognitive functioning at three points during the course of treatment (T0, T1, T2).Results: The results of the paired sample t-tests showed the scores on the Fact-Cog test confirmed significant cognitive decline for both treatment groups from baseline (T0) to completion (T2) of chemotherapy; CMF group, t (9) = 2.91, p = 0.017 and the FAC group t (19) = 4.66, p 0.001.Conclusion: This study confirms that self-reported subjective cognitive impairment is common in breast cancer patients who received chemotherapy in a sample of South African patients. The results have implications for the overall care of cancer patients.Contribution: The context-based knowledge engendered by the current study is expected to augment the continuum of care for breast cancer patients.

scholarly journals An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Alexandre Chan ◽  
Angie Yeo ◽  
Maung Shwe ◽  
Chia Jie Tan ◽  
Koon Mian Foo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cognitive Function ◽  
Cancer Patients ◽  
Dna Methyltransferase ◽  
Dna Methyltransferases ◽  
Breast Cancer Patients ◽  
Prospective Longitudinal Study ◽  
Cognitive Domains ◽  
Prospective Longitudinal

Abstract Strong evidence suggests that genetic variations in DNA methyltransferases (DNMTs) may alter the downstream expression and DNA methylation patterns of neuronal genes and influence cognition. This study investigates the association between a DNMT1 polymorphism, rs2162560, and chemotherapy-associated cognitive impairment (CACI) in a cohort of breast cancer patients. This is a prospective, longitudinal cohort study. From 2011 to 2017, 351 early-stage breast cancer patients receiving chemotherapy were assessed at baseline, the midpoint, and the end of chemotherapy. DNA was extracted from whole blood, and genotyping was performed using Sanger sequencing. Patients’ self-perceived cognitive function and cognitive performance were assessed at three different time points using FACT-Cog (v.3) and a neuropsychological battery, respectively. The association between DNMT1 rs2162560 and cognitive function was evaluated using logistic regression analyses. Overall, 33.3% of the patients reported impairment relative to baseline in one or more cognitive domains. Cognitive impairment was observed in various objective cognitive domains, with incidences ranging from 7.2% to 36.9%. The DNMT1 rs2162560 A allele was observed in 21.8% of patients and this was associated with lower odds of self-reported cognitive decline in the concentration (OR = 0.45, 95% CI: 0.25–0.82, P = 0.01) and functional interference (OR = 0.48, 95% CI: 0.24–0.95, P = 0.03) domains. No significant association was observed between DNMT1 rs2162560 and objective cognitive impairment. This is the first study to show a significant association between the DNMT1 rs2162560 polymorphism and CACI. Our data suggest that epigenetic processes could contribute to CACI, and further studies are needed to validate these findings.

Sign in / Sign up

Export Citation Format

Share Document